NSC 95397
Based on 9 publication(s) in Google Scholar
NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (Ki=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC50=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)). NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.0%
- CAS 番号: 93718-83-3
- 分子式: C14H14O4S2
- 分子量:310.39
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Phosphatase Inhibitor Library
HY-L081
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
MedChemExpress（MCE）の使用を引用している文献 NSC 95397
More- J Neuroinflammation. 2024 Oct 10;21(1):259. [Abstract]
- Phytomedicine. 2021 Nov;92:153743. [Abstract]
- Cell Biol Toxicol. 2025 Dec 18;42(1):1. [Abstract]
- Biol Direct. 2024 Jun 21;19(1):48. [Abstract]
- Bioengineered. 2022 May;13(5):13089-13107. [Abstract]
- J Cancer Res Clin Oncol. 2024 May 7;150(5):239. [Abstract]
- Biochem Biophys Res Commun. 2026 Feb 26:802:153342. [Abstract]
- Cell Physiol Biochem. 2016;40(3-4):597-607. [Abstract]
- bioRxiv. 2024 Feb 5.
生物活性
Ki: 32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C)[1]
IC50: 22.3 nM (human Cdc25A) , 56.9 nM (human Cdc25C), 125 nM (Cdc25B)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
1.45 μM
Compound: NCS 95397
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 28431339] |
| A549 | IC50 |
13.1 μM
Compound: 4; NSC 95397
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| HeLa | IC50 |
10.8 μM
Compound: NSC-95397
|
Cytotoxicity against human HeLa cells after 6 days by WST1 colorimetric assay
Cytotoxicity against human HeLa cells after 6 days by WST1 colorimetric assay
|
[PMID: 18789703] |
| HeLa | IC50 |
8.5 μM
Compound: NSC-95397
|
Antiproliferative activity against human HeLa cells after 10 days by clonogenic assay
Antiproliferative activity against human HeLa cells after 10 days by clonogenic assay
|
[PMID: 18789703] |
| HL-60 | IC50 |
1 μM
Compound: 4; NSC 95397
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| Hs 683 | IC50 |
2.8 μM
Compound: NCS 95397
|
Cytotoxicity against human Hs683 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human Hs683 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 28431339] |
| Jurkat | IC50 |
3.7 μM
Compound: 4; NSC 95397
|
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| LS174T | IC50 |
18.1 μM
Compound: 4; NSC 95397
|
Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| MCF7 | IC50 |
0.96 μM
Compound: NCS 95397
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 28431339] |
| MCF7 | IC50 |
9.4 μM
Compound: 4; NSC 95397
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| MONO-MAC-6 | IC50 |
4.2 μM
Compound: 4; NSC 95397
|
Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| PBMC | IC50 |
7.8 μM
Compound: 4; NSC 95397
|
Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| PC-3 | IC50 |
3.4 μM
Compound: NCS 95397
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 28431339] |
| SK-MEL-28 | IC50 |
2.3 μM
Compound: NCS 95397
|
Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 28431339] |
| SW982 | IC50 |
7.9 μM
Compound: 4; NSC 95397
|
Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| THP-1 | IC50 |
1.4 μM
Compound: 4; NSC 95397
|
Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
| U-937 | IC50 |
3.9 μM
Compound: 4; NSC 95397
|
Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 31563013] |
NSC 95397 (0, 10, and 20 μM; 24 hour) decreases the cell viability of three colon cancer cell lines SW480, SW620, and DLD-1 in a concentration-dependent manner[2].
?
NSC 95397(10 μM; 24 hour) upregulates p21 while downregulates CDK4 and CDK6 were d in all three colon cancer cell lines SW480, SW620, and DLD-1 cells[2].
?
NSC 95397 (10 μM;? 24 hour) reduces the phosphorylation of retinoblastoma protein (Rb) on Ser795 and Ser807/811[2].
?
NSC 95397 (20 μM; 24 hours) significantly increases cleaved caspase-9, -3, -7 and PARP levels[2].
?
NSC 95397 (10 μM; 6 hours) enhances the phosphorylation of its downstream ERK1/2 at Thr202/Tyr 204[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human colon cancer cell lines, SW480, SW620, and DLD-1
-
Concentration:0, 10, and 20 µM
-
Incubation Time:24 hours
-
Result:The IC50 values of NSC 95397 for the cell growth of SW480, SW620, and DLD-1 cells were 9.9, 14.1 and 18.6 μM, respectively.
-
Cell Line:SW480, SW620, and DLD-1 cells
-
Concentration:10 μM
-
Incubation Time:24 hours
-
Result:p21 was upregulated while CDK4 and CDK6 were downregulated.
Rduced the phosphorylation of Rb on Ser795 and Ser807/811
化学情報
-
CAS 番号 93718-83-3
-
性状 Solid
-
分子量 310.39
-
分子式 C14H14O4S2
-
Color Light yellow to orange
-
SMILES
O=C1C(SCCO)=C(SCCO)C(C2=C1C=CC=C2)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
J Neuroinflammation
Melanin concentrating hormone regulates the JNK/ERK signaling pathway to alleviate influenza A virus infection-induced neuroinflammation. [Abstract]2024 Oct 10;21(1):259. PMID: 39390522 -
Phytomedicine
Shaoyao decoction attenuates DSS-induced ulcerative colitis, macrophage and NLRP3 inflammasome activation through the MKP1/NF-κB pathway. [Abstract]2021 Nov;92:153743. PMID: 34583225 -
Cell Biol Toxicol
CtBP1-LSD1 complex drives ErbB2 activation via H3K9me2 demethylation in DRGs during paclitaxel-induced neuropathic pain. [Abstract]2025 Dec 18;42(1):1. PMID: 41410814 -
Biol Direct
PNSC928, a plant-derived compound, specifically disrupts CtBP2-p300 interaction and reduces inflammation in mice with acute respiratory distress syndrome. [Abstract]2024 Jun 21;19(1):48. PMID: 38902802 -
Bioengineered
CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma. [Abstract]2022 May;13(5):13089-13107. PMID: 35615982 -
J Cancer Res Clin Oncol
KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway. [Abstract]2024 May 7;150(5):239. PMID: 38713252 -
Biochem Biophys Res Commun
Inhibition of CDC25C attenuates IL-17A-driven keratinocyte hyperproliferation and psoriasis progression. [Abstract]2026 Feb 26:802:153342. PMID: 41587503 -
Cell Physiol Biochem
2016;40(3-4):597-607. PMID: 27889774 -
溶剤 & 溶解度
DMSO : ≥ 100 mg/mL (322.18 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 10 mg/mL (32.22 mM); Clear solution
This protocol yields a clear solution of ≥ 10 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 10 mg/mL (32.22 mM); Clear solution
This protocol yields a clear solution of ≥ 10 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Lazo JS, et al. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol. 2002 Apr;61(4):720-8. [Content Brief]
[2]. Dubey NK, et al. NSC 95397 Suppresses Proliferation and Induces Apoptosis in Colon Cancer Cells through MKP-1 and the ERK1/2 Pathway. Int J Mol Sci. 2018 May 31;19(6). pii: E1625. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2218 mL | 16.1088 mL | 32.2175 mL | 80.5438 mL |
| 5 mM | 0.6444 mL | 3.2218 mL | 6.4435 mL | 16.1088 mL | |
| 10 mM | 0.3222 mL | 1.6109 mL | 3.2218 mL | 8.0544 mL | |
| 15 mM | 0.2148 mL | 1.0739 mL | 2.1478 mL | 5.3696 mL | |
| 20 mM | 0.1611 mL | 0.8054 mL | 1.6109 mL | 4.0272 mL | |
| 25 mM | 0.1289 mL | 0.6444 mL | 1.2887 mL | 3.2218 mL | |
| 30 mM | 0.1074 mL | 0.5370 mL | 1.0739 mL | 2.6848 mL | |
| 40 mM | 0.0805 mL | 0.4027 mL | 0.8054 mL | 2.0136 mL | |
| 50 mM | 0.0644 mL | 0.3222 mL | 0.6444 mL | 1.6109 mL | |
| 60 mM | 0.0537 mL | 0.2685 mL | 0.5370 mL | 1.3424 mL | |
| 80 mM | 0.0403 mL | 0.2014 mL | 0.4027 mL | 1.0068 mL | |
| 100 mM | 0.0322 mL | 0.1611 mL | 0.3222 mL | 0.8054 mL |
Powered by Bioz